Biosimilar Antibodies

Sabatolimab (MBG453) is a high-affinity, humanized IgG4 (S228P) monoclonal antibody designed to specifically target TIM-3, an inhibitory receptor involved in the regulation of both adaptive and innate immune responses. This antibody serves as a potential agent for immunosuppression, targeting TIM-3 expressed on various immune and myeloid cells. Sabatolimab's specificity and mechanism of action make it a valuable tool for research in immune regulation and potential therapeutic applications in diseases characterized by immune dysregulation.

Indusatumab, designated as 5F9, is a monoclonal antibody specifically targeting human Guanylate Cyclase 2C (GUCY2C). This antibody is developed for high specificity and affinity, making it an essential tool for research into GUCY2C's role in cellular signaling and potential implications in gastrointestinal diseases and cancers.

Iscalimab (CFZ-533) is a non-depleting IgG1 monoclonal antibody that selectively targets CD40 with a dissociation constant (K_D) of 0.3 nM. This high-affinity interaction underscores its utility in the study of immunological disorders, including Graves' hyperthyroidism and various autoimmune diseases. Iscalimab is engineered to modulate the CD40-CD40L pathway, pivotal in immune regulation, without causing depletion of immune cells, making it an ideal tool for advanced immunological research and therapeutic investigations.

Anti-SARS-CoV-2 Spike mAb (CR3022) is a human monoclonal IgG1 antibody produced in CHO cells. This antibody specifically binds to the S1 domain of the Spike protein present in both SARS-CoV and SARS-CoV-2, offering potential utility in the study of viral mechanisms and therapeutic development against COVID-19.

The Anti-CD69 Antibody is a human-derived monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the CD69 molecule. This antibody has a predicted molecular weight of 150 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended. This product is essential for research focused on the activation and regulation of T and B lymphocytes, as CD69 is an early activation marker in these cell types.

The Anti-MICB Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets the MHC class I polypeptide-related sequence B (MICB), a stress-induced ligand involved in immune recognition by natural killer (NK) cells and certain T cells. This antibody is composed of a human IgG2 heavy chain and a human kappa light chain, with an approximate molecular weight of 143.66 kDa. For experimental control purposes, Human IgG2 kappa, Isotype Control is recommended.

The Anti-CXCR3/GPR9/CD183 Antibody is derived from human sources and expressed in Chinese Hamster Ovary (CHO) cells. This antibody specifically targets the CXCR3/GPR9/CD183 receptor, which is implicated in various immunological responses. Featuring a human IgG1 heavy chain and a human kappa light chain, this antibody has a predicted molecular weight of 150 kDa. For isotype control purposes, reference is made to the Human IgG1 kappa, Isotype Control, ensuring accurate and reliable experimental results.

Anti-CTLA-4/CD152 Antibody (BN13) is a chimeric mouse IgG2a, κ antibody designed to target human CTLA-4/CD152. For isotype control, it is recommended to use Mouse IgG2a kappa, Isotype Control, ensuring specificity and consistency in antibody performance.

Aplitabart is a humanized IgM-κ antibody that specifically targets TNFRSF10B. This monoclonal antibody is designed for precise interaction with the TNFRSF10B receptor, which plays a critical role in the regulation of apoptosis. Aplitabart is utilized primarily in research focused on cancer biology, particularly in studies investigating the mechanisms of programmed cell death and potential therapeutic interventions.

Faricimab is a bispecific antibody that simultaneously targets Angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A), exhibiting a favorable safety and tolerability profile. This therapeutic agent is designed to inhibit retinal vascular leakage, cell death, and inflammation, which are critical pathological factors in retinal ischemia/reperfusion (I/R) injury and subretinal choroidal neovascularization (sCNV) in mouse models. Clinical studies have shown that Faricimab offers statistically significant improvements in visual acuity compared to Ranibizumab. It is indicated for the treatment of various retinal diseases, including wet age-related macular degeneration (w-AMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), making it a valuable tool in ophthalmic research and therapeutic applications.

NEO-201 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting CEACAM6/CD66c. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, with an estimated molecular weight of 145.48 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended.

The Anti-BRCA1 Antibody (BR64) is a chimeric mouse monoclonal antibody of the IgG1, κ subclass, specifically designed to target human BRCA1. For accurate experimental control, it is recommended to use Mouse IgG1 kappa Isotype Control alongside this antibody.

Denintuzumab (hBU 12) is a recombinant humanized monoclonal antibody targeting CD19. This antibody serves as a critical component in the development of antibody-drug conjugates (ADCs), specifically in the synthesis of Denintuzumab Mafodotin (SGN-CD19A). Denintuzumab Mafodotin is primarily utilized in research focused on acute lymphoblastic leukemia, providing a targeted therapeutic approach by delivering cytotoxic drugs directly to CD19-expressing cells. This specificity makes Denintuzumab an invaluable tool in the advancement of leukemia therapeutics.

The Anti-IFNAR1 Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the Interferon alpha/beta receptor 1 (IFNAR1). This antibody comprises a human IgG1 heavy chain and a human kappa light chain, with a predicted molecular weight of 144.92 kDa. For isotype control, Human IgG1 kappa, Isotype Control is recommended. This product is essential for research focusing on the signaling pathways and immunological responses mediated by IFNAR1.

Tigatuzumab (CS-1008) is a humanized IgG1 monoclonal antibody that specifically targets Death Receptor 5 (DR5). This antibody facilitates the induction of apoptosis in cancer cells and has demonstrated the ability to inhibit tumor growth in vivo. Tigatuzumab is primarily utilized in cancer research, offering potential insights into therapeutic strategies for targeting apoptotic pathways in oncology.

Vixticibart is a human monoclonal antibody of the IgG4κ subtype, specifically targeting NPR1. For experimental control purposes, it is recommended to use Human IgG4 (S228P) kappa as an isotype control.

The Anti-CD71 Antibody (OKT-9) is a chimeric mouse monoclonal antibody of the IgG1κ subclass, specifically designed to target human CD71. For accurate experimental control, it is recommended to use Mouse IgG1 kappa as an isotype control. This antibody is essential for studies focusing on the CD71 transmembrane protein, commonly known as the transferrin receptor, which plays a crucial role in iron uptake and cellular proliferation.

Inclacumab is a recombinant human monoclonal IgG4 antibody that exhibits high selectivity for P-selectin, with a dissociation constant (Kd) of 9.9 nM. This antibody effectively inhibits the interaction between P-selectin and its ligand, P-selectin glycoprotein ligand 1 (PSGL-1), with a half-maximal inhibitory concentration (IC50) of 1.9 μg/mL. It is particularly effective in blocking cell adhesion mediated by P-selectin, making it a valuable tool for research into inflammatory and cardiovascular diseases where P-selectin plays a key role.

The Anti-c-Myc Antibody (9E10) is a chimeric mouse monoclonal antibody of the IgG1 subtype, specifically designed to target the human c-Myc protein. For accurate isotype control in experimental setups, it is recommended to use Mouse IgG1 kappa Isotype Control. This antibody is ideal for research applications focusing on cellular processes involving the c-Myc protein.

Zimistobart (BMS-986315) is a fully human IgG1 monoclonal antibody specifically designed to target NKG2A, a receptor involved in the modulation of immune responses. This antibody is particularly useful in research focused on non-small cell lung cancer (NSCLC), providing a valuable tool for studies aimed at understanding and potentially manipulating immune evasion mechanisms in cancer cells. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended.

Ezabenlimab (BI-754091) is a monoclonal antibody targeting the programmed death-1 (PD-1) receptor, exhibiting a binding affinity with a dissociation constant (Kd) of 6 nM, as determined in CHO cell assays. This antibody effectively inhibits the interaction between PD-1 and its ligands PD-L1 and PD-L2, thereby enhancing interferon-γ secretion in T cells. The blockade of this pathway by Ezabenlimab has demonstrated the ability to inhibit tumor growth in vivo, highlighting its potential utility in oncological research and therapeutic applications.

NC-318 (5G-12) is a human-derived monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting Siglec-15/CD33L3. This antibody is composed of a human IgG1 type heavy chain and a human kappa type light chain, with a predicted molecular weight of 146.98 kDa. For experimental control purposes, the appropriate isotype control is Human IgG1 kappa.

Gancotamab (MM-302) is a conjugate of a HER2-targeted antibody and liposomal Doxorubicin, designed to enhance the delivery of Doxorubicin directly to tumor cells expressing high levels of HER2. This formulation capitalizes on the specificity of monoclonal antibodies for HER2 to selectively target and exert antitumor activity, thereby potentially improving therapeutic efficacy and reducing systemic toxicity. Gancotamab is primarily utilized in research focused on the treatment of HER2-positive cancers.

Cugrastomig is a chimeric antibody of the IgG1κ-[scFv-heavy -κ]2 class, designed to target both PDCD1 and LAG3. This antibody incorporates both human and humanized components, optimizing it for enhanced specificity and efficacy in therapeutic applications that involve modulation of immune checkpoints.

Zansecimab (LY-3127804) is a monoclonal antibody of the immunoglobulin G4-kappa subclass, specifically targeting angiopoietin 2 (Ang 2). This antibody is designed for potential use in studies focused on angiogenesis and immune regulation, providing a valuable tool for research in these critical areas of biological and medical science.

Mozistobart is a humanized IgG1κ monoclonal antibody that specifically targets CD22. For experimental controls, the recommended isotype control is Human IgG1 kappa.

Lenvervimab (GC1102) is a recombinant human immunoglobulin of the IgG1 subtype, specifically designed for the study of Hepatitis B virus (HBV) infections. This monoclonal antibody targets key antigens associated with HBV, making it a valuable tool for researchers investigating the pathogenesis, immune response, and potential therapeutic interventions for Hepatitis B.

NGM-621 is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets Complement C3, a critical component of the complement system involved in immune responses. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, with a predicted molecular weight of 149.04 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended.

Talquetamab (JNJ-64407564) is a humanized bispecific antibody engineered to target GPRC5D, a member of the G protein-coupled receptor family C group D, and CD3, a key component in T-cell activation. This antibody facilitates the recruitment and activation of T cells, leading to the selective killing of multiple myeloma (MM) cells expressing GPRC5D. Demonstrating significant antitumor activity, Talquetamab is pivotal in advancing therapeutic strategies for MM treatment through its dual targeting mechanism.

The Anti-CLEC7A Antibody is a humanized monoclonal antibody produced in Chinese hamster ovary (CHO) cells, specifically designed to target CLEC7A (C-type lectin domain family 7 member A). This antibody has a predicted molecular weight of 150 kDa. For isotype control, it is recommended to use Human IgG4 kappa, Isotype Control, which serves as a standard in experiments to help distinguish specific from non-specific binding. This product is essential for researchers focusing on the role of CLEC7A in immune response and its implications in various inflammatory and infectious diseases.

Vapaliximab (2D10) is a monoclonal antibody specifically designed to target and bind to human vascular adhesion protein-1 (VAP-1). This antibody is utilized primarily in research focused on inflammatory processes and vascular biology, providing insights into the role of VAP-1 in disease mechanisms and potential therapeutic interventions.

AMG-820 is a fully human monoclonal antibody of the IgG2 isotype specifically designed to target CSF-1R (Colony Stimulating Factor 1 Receptor). This antibody effectively blocks the binding of its natural ligands, CSF1 and IL34, thereby inhibiting receptor activation induced by these ligands. For experimental control purposes, the Human IgG2 kappa, Isotype Control is recommended as a suitable isotype control for AMG-820. This product is essential for research focused on the modulation of CSF-1R activity, particularly in studies related to inflammation and cancer where CSF-1R plays a critical role.

Abrezekimab (VR 942), featuring CDP7766, is a humanized, high-affinity monoclonal antibody fragment with neutralizing properties against human interleukin-13 (IL-13). It specifically binds to IL-13, effectively preventing interaction with the IL-13Rα1 receptor subunit. This antibody is primarily utilized in asthma research to investigate the role and therapeutic potential of IL-13 inhibition in disease pathogenesis and progression.

Efpegsomatropin is a conjugate composed of human growth hormone linked to an Fc peptide, designed to enhance molecular stability and extend serum half-life. This conjugate is ideal for use in a range of biochemical studies, including investigations into growth hormone signaling pathways and the pharmacokinetics of peptide hormones. Its unique structure makes it a valuable tool for researchers studying the regulation of growth and metabolism.

Gentulizumab (Gensci-059) is a humanized IgG4 monoclonal antibody specifically designed to target CD47. This antibody demonstrates robust binding affinity for CD47 across both human and monkey tissues, effectively disrupting the CD47-SIRPα interaction. Such inhibition plays a critical role in modulating antitumor immunity, making Gentulizumab a potent agent for antitumor activity studies. For experimental control purposes, Human IgG4 (S228P) kappa serves as the appropriate isotype control for Gentulizumab.

Ersodetug is a human IgG2 κ monoclonal antibody targeting the insulin receptor (INSR). For experimental control purposes, it is recommended to use Human IgG2 kappa as an isotype control.

Rozanolixizumab (UCB7665) is a humanized, high-affinity monoclonal antibody targeting the human neonatal Fc receptor (FcRn). Classified as an IgG4P isotype, this antibody is primarily utilized in research focused on the reduction of pathogenic IgG in various autoimmune and alloimmune disorders. Its specific interaction with FcRn highlights its potential for modulating immune responses and antibody recycling, making it a valuable tool for studies in immunology and therapeutic development.

REGN5054 is a fully human monoclonal IgG1 antibody designed to bind specifically to CD8 antigens expressed on T cells in both human and cynomolgus models. This antibody provides a valuable tool for the study of T-cell function and the role of CD8 in immune responses.

Indemakitug is a human monoclonal antibody of the IgG1λ2 subtype that specifically targets interferon-gamma (IFNG). For experimental control purposes, it is recommended to use Human IgG1 lambda2 as an isotype control.

The Anti-TPBG Antibody (PF-06263507) is a humanized monoclonal antibody, produced in Chinese Hamster Ovary (CHO) cells, designed to specifically target TPBG. This antibody is comprised of a human IgG1 type heavy chain and a human kappa type light chain, with an estimated molecular weight of 145.8 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended. This antibody serves as a valuable tool for research focused on the biological functions and pathological roles of TPBG.

Mibavademab is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting LEPR/CD295. This antibody is comprised of a human IgG4SP heavy chain and a human kappa light chain, exhibiting a predicted molecular weight of 145.58 kDa. For experimental control purposes, the appropriate isotype control is Human IgG4 kappa.

Citatuzumab bogatox (VB6-845) is a recombinant immunotoxin consisting of a humanized antibody Fab fragment targeting epithelial cell adhesion molecule (EpCAM) linked to a modified cytotoxin, bouganin. This agent binds selectively to EpCAM-positive cell lines, inducing apoptosis effectively. Citatuzumab bogatox demonstrates robust activity in EpCAM-positive human tumor xenograft models, highlighting its potential for targeted cancer therapy applications.

Lebrikizumab (TNX-650) is a humanized IgG4 monoclonal antibody that targets interleukin-13 (IL-13), binding specifically to a non-receptor binding domain of IL-13 to inhibit its activity. This antibody effectively blocks the IL-13-driven Th2 inflammatory response by interfering with the signaling pathway involving IL-4Rα/IL-13Rα1. Lebrikizumab also exhibits anti-itch properties, making it a valuable tool for research into asthma, atopic dermatitis, and neuroinflammatory disorders.

The Anti-PTPRC/CD45 Antibody is a human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target the protein tyrosine phosphatase receptor type C (PTPRC), also known as CD45. This antibody is constructed with a human IgG1 heavy chain and a human kappa light chain, and exhibits a predicted molecular weight of 150 kDa. For experimental control purposes, the Human IgG1 kappa, Isotype Control is recommended. This antibody is essential for research focusing on immune cell signaling and function, as CD45 is pivotal in activating and regulating T and B cell receptor signaling pathways.

Cenvacibart is a monoclonal antibody designed to inhibit coagulation factor XI (F11), a key protein in the coagulation cascade. By targeting and blocking the activity of factor XI, Cenvacibart effectively reduces thrombus formation. This antibody is particularly valuable in the study of thrombotic disorders, offering a promising tool for researchers exploring the mechanisms and potential treatments of these conditions.

Zampilimab (UCB-7858) is a monoclonal antibody specifically targeting transglutaminase 2 (TG2). This antibody demonstrates potential utility in enhancing the outcomes of renal transplantation. Zampilimab has been developed to modulate immune responses, potentially reducing the risk of transplant rejection and improving graft survival. Its precise mechanism involves the inhibition of TG2, an enzyme implicated in inflammation and tissue fibrosis. This product is pivotal for research focused on transplant immunology and the development of therapeutic strategies to increase transplant success rates.

Atigotatug is a humanized IgG1κ monoclonal antibody specifically targeting Fucosyl ganglioside GM1. For experimental control purposes, it is recommended to use Human IgG1 kappa as an isotype control.

Apamistamab is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting PTPRC/CD45. This antibody is composed of a human IgG1 type heavy chain and a human kappa (huκ) type light chain, exhibiting a predicted molecular weight of 146.52 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended.